Zobrazeno 1 - 10
of 152
pro vyhledávání: '"H. M. Jansen"'
Autor:
Elisabeth M. Jongbloed, Maurice P. H. M. Jansen, Vanja de Weerd, Jean A. Helmijr, Corine M. Beaufort, Marcel J. T. Reinders, Ronald van Marion, Wilfred F. J. van IJcken, Gabe S. Sonke, Inge R. Konings, Agnes Jager, John W. M. Martens, Saskia M. Wilting, Stavros Makrodimitris
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-11 (2023)
Abstract Next generation sequencing of cell-free DNA (cfDNA) is a promising method for treatment monitoring and therapy selection in metastatic breast cancer (MBC). However, distinguishing tumor-specific variants from sequencing artefacts and germlin
Externí odkaz:
https://doaj.org/article/25950c21f0c9448e94b13a8b82eb4ebd
Autor:
Silvia R. Vitale, Kirsten Ruigrok-Ritstier, A. Mieke Timmermans, Renée Foekens, Anita M. A. C. Trapman-Jansen, Corine M. Beaufort, Paolo Vigneri, Stefan Sleijfer, John W. M. Martens, Anieta M. Sieuwerts, Maurice P. H. M. Jansen
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-16 (2022)
Abstract Background In breast cancer (BC), recurrent fusion genes of estrogen receptor alpha (ESR1) and AKAP12, ARMT1 and CCDC170 have been reported. In these gene fusions the ligand binding domain of ESR1 has been replaced by the transactivation dom
Externí odkaz:
https://doaj.org/article/5619f8611366419781ebf77950eb8c5c
Autor:
Jose Espejo Valle-Inclan, Christina Stangl, Anouk C. de Jong, Lisanne F. van Dessel, Markus J. van Roosmalen, Jean C. A. Helmijr, Ivo Renkens, Roel Janssen, Sam de Blank, Chris J. de Witte, John W. M. Martens, Maurice P. H. M. Jansen, Martijn P. Lolkema, Wigard P. Kloosterman
Publikováno v:
Genome Medicine, Vol 13, Iss 1, Pp 1-14 (2021)
Abstract Here, we describe a novel approach for rapid discovery of a set of tumor-specific genomic structural variants (SVs), based on a combination of low coverage cancer genome sequencing using Oxford Nanopore with an SV calling and filtering pipel
Externí odkaz:
https://doaj.org/article/dc2d84df5339442da6944319858a489d
Autor:
Silvia R. Vitale, Jean A. Helmijr, Marjolein Gerritsen, Hicret Coban, Lisanne F. van Dessel, Nick Beije, Michelle van der Vlugt-Daane, Paolo Vigneri, Anieta M. Sieuwerts, Natasja Dits, Martin E. van Royen, Guido Jenster, Stefan Sleijfer, Martijn Lolkema, John W. M. Martens, Maurice P. H. M. Jansen
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-17 (2021)
Abstract Background Extracellular vesicles (EVs) are actively secreted by cells into body fluids and contain nucleic acids of the cells they originate from. The goal of this study was to detect circulating tumor-derived EVs (ctEVs) by mutant mRNA tra
Externí odkaz:
https://doaj.org/article/72f7c191e7ba46759ff2867e41682c33
Autor:
Manouk K. Bos, Kazem Nasserinejad, Maurice P. H. M. Jansen, Christi M.J. Steendam, Lindsay Angus, Peggy N. Atmodimedjo, Evert deJonge, Winand N. M. Dinjens, Ron H. N. vanSchaik, Marzia Del Re, Hendrikus J. Dubbink, Stefan Sleijfer, John W. M. Martens
Publikováno v:
Molecular Oncology, Vol 15, Iss 1, Pp 57-66 (2021)
Quantification of tumor‐specific variants (TSVs) in cell‐free DNA is rapidly evolving as a prognostic and predictive tool in patients with cancer. Currently, both variant allele frequency (VAF) and number of mutant molecules per mL plasma are use
Externí odkaz:
https://doaj.org/article/3e8c396276a3456a805bd06c9ab88dde
Autor:
Aad van der Lugt, Dik C van Gent, Gerda M Verduijn, Marta E Capala, Nienke D Sijtsema, Iris Lauwers, Juan A Hernandez Tamames, Wilma D Heemsbergen, Aniel Sewnaik, Jose A Hardillo, Hetty Mast, Yvette van Norden, Maurice P H M Jansen, Mischa S Hoogeman, Bianca Mostert, Steven F Petit
Publikováno v:
BMJ Open, Vol 12, Iss 5 (2022)
Introduction The locoregional failure (LRF) rate in human papilloma virus (HPV)-negative oropharyngeal squamous cell carcinoma (OPSCC) remains disappointingly high and toxicity is substantial. Response prediction prior to or early during treatment wo
Externí odkaz:
https://doaj.org/article/19f15ce4516e4b28ada070fa85e6367a
Autor:
M. K. Bos, S. W. Lam, G. Motta, J. C. A. Helmijr, C. M. Beaufort, E. de Jonge, J. W. M. Martens, E. Boven, M. P. H. M. Jansen, A. Jager, S. Sleijfer
Publikováno v:
Bos, M K, Lam, S W, Motta, G, Helmijr, J C A, Beaufort, C M, de Jonge, E, Martens, J W M, Boven, E, Jansen, M P H M, Jager, A & Sleijfer, S 2023, ' Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer ', Breast Cancer Research and Treatment, vol. 200, no. 2, pp. 271-279 . https://doi.org/10.1007/s10549-023-06965-5
Breast Cancer Research and Treatment, 200(2), 271-279. Springer New York
Breast Cancer Research and Treatment, 200(2), 271-279. Springer New York
Background ESR1 mutations have been identified as mechanism for endocrine resistance and are also associated with a decreased overall survival. We assessed ESR1 mutations in circulating tumor DNA (ctDNA) for impact on outcome to taxane-based chemothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7aebbcd0120eb600dc370a3b31b7216
https://pure.eur.nl/en/publications/00ba171e-1ab7-4e84-bef7-427b3ddafd1e
https://pure.eur.nl/en/publications/00ba171e-1ab7-4e84-bef7-427b3ddafd1e
Autor:
Erik J. vanHelden, Lindsay Angus, C. Willemien Menke‐van der Houven van Oordt, Daniëlle A. M. Heideman, Eline Boon, Suzanne C. vanEs, Sandra A. Radema, Carla M. L. vanHerpen, Derk Jan A. deGroot, Elisabeth G. E. deVries, Maurice P. H. M. Jansen, Stefan Sleijfer, Henk M. W. Verheul
Publikováno v:
Molecular Oncology, Vol 13, Iss 11, Pp 2361-2374 (2019)
In metastatic colorectal cancer, RAS and BRAF mutations cause resistance to anti‐EGFR therapies, such as cetuximab. Heterogeneity in RAS and BRAF mutations might explain nonresponse in a subset of patients receiving cetuximab. Analyzing mutations i
Externí odkaz:
https://doaj.org/article/55eb68fb8dbf4d9b8e6e70877c64b61e
Autor:
Lisanne F. vanDessel, Silvia R. Vitale, Jean C. A. Helmijr, Saskia M. Wilting, Michelle van derVlugt‐Daane, Esther Oomen‐de Hoop, Stefan Sleijfer, John W. M. Martens, Maurice P. H. M. Jansen, Martijn P. Lolkema
Publikováno v:
Molecular Oncology, Vol 13, Iss 2, Pp 392-402 (2019)
The emerging interest in circulating tumor DNA (ctDNA) analyses for clinical trials has necessitated the development of a high‐throughput method for fast, reproducible, and efficient isolation of ctDNA. Currently, the majority of ctDNA studies use
Externí odkaz:
https://doaj.org/article/b0ed0522c4144c57ae8f5ab41d58ef36
Autor:
Nick Beije, Anieta M. Sieuwerts, Jaco Kraan, Ngoc M. Van, Wendy Onstenk, Silvia R. Vitale, Michelle van derVlugt‐Daane, Luc Y. Dirix, Anja Brouwer, Paul Hamberg, Felix E. deJongh, Agnes Jager, Caroline M. Seynaeve, Maurice P. H. M. Jansen, John A. Foekens, John W. M. Martens, Stefan Sleijfer
Publikováno v:
Molecular Oncology, Vol 12, Iss 1, Pp 48-57 (2018)
Mutations and splice variants in the estrogen receptor (ER) gene, ESR1, may yield endocrine resistance in metastatic breast cancer (MBC) patients. These putative endocrine resistance markers are likely to emerge during treatment, and therefore, its d
Externí odkaz:
https://doaj.org/article/a96c0aa2bd0e46b1b935378b90044e34